We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.35% | 65.50 | 19.23 | 69.79 | 66.3507 | 64.63 | 65.50 | 12,382,427 | 05:00:04 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Agenus Inc. (AGEN) on Thursday said the U.S. Food and Drug Administration accepted the company's investigational new drug application for AGEN2373, triggering a $7.5 million milestone payment from Gilead Sciences Inc. (GILD).
The Lexington, Mass., clinical-stage immuno-oncology company in December formed a partnership with Gilead to develop and commercialize up to five novel immuno-oncology therapies.
Under the deal, Agenus received $150 million upfront from Gilead and is eligible for roughly $1.7 billion in future fees and milestones.
"AGEN2373 has unique binding properties and is designed to mitigate the toxicity observed with competitor molecules," Agenus said. "We believe that this molecule has great potential for patients with cancer."
Shares of Agenus rose 3.2% in premarket trading Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 08, 2019 09:08 ET (13:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
